Expertise in
8
conditions

Dr. Desiree Doncals

Radiation Oncology
Summa Health Medical Group Radiation Oncology
161 N Forge St Ste G90, 
Akron, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
8
conditions
Summa Health Medical Group Radiation Oncology
161 N Forge St Ste G90, 
Akron, OH 

Overview

Desiree Doncals is a Radiation Oncologist practicing medicine in Akron, Ohio.

Dr. Doncals is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Prostate Cancer, Pleuropulmonary Blastoma, and Primitive Neuroectodermal Tumor (PNET).

She is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 12 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in OH

Hospital Affiliations

Summa Health System

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
SummaCare
  • HMO
  • PPO
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Summa Health Medical Group Radiation Oncology
161 N Forge St Ste G90, Akron, OH 44304

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients With DCIS Following Breast Conserving Therapy
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients With DCIS Following Breast Conserving Therapy
Enrollment Status: Recruiting
Publish Date: September 19, 2024
Intervention Type: Device, Other
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2026
Intervention Type: Drug, Radiation
Study Drugs: Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Relugolix, Triptorelin
Study Phase: Phase 3
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: March 02, 2026
Intervention Type: Radiation
Study Phase: Phase 2/Phase 3
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 23, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Radiation
Study Phase: Phase 3
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 3
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Unknown
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
View 9 Less Clinical Trials

11 Total Publications

Patient-Reported Outcomes During Pelvic Radiation Therapy: A Secondary Analysis on Sexual Function From NRG-RTOG 1203.
Patient-Reported Outcomes During Pelvic Radiation Therapy: A Secondary Analysis on Sexual Function From NRG-RTOG 1203.
Journal: JCO oncology advances
Published: October 22, 2024
Similar Doctors
Expertise in
52
conditions
Dr. Samuel Chao
Radiation Oncology
Expertise in
52
conditions
Dr. Samuel Chao
Radiation Oncology

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (29.7 miles away)
866-223-8100
Experience:
29+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Samuel Chao is a Radiation Oncologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 29 years. Dr. Chao is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Astrocytoma, Glioma, Glioblastoma, and Gamma Knife Radiosurgery. Dr. Chao is board certified in American Board Of Radiology, 2007.

Expertise in
51
conditions
Dr. John Suh
Radiation Oncology
Expertise in
51
conditions
Dr. John Suh
Radiation Oncology

Office

10201 Carnegie Ave, 
Cleveland, OH 
 (29.7 miles away)
216-444-5571
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Suh is a Radiation Oncologist practicing medicine in Cleveland, Ohio. Dr. Suh is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioma, Glioblastoma, Astrocytoma, and Gamma Knife Radiosurgery.

Expertise in
15
conditions
Dr. James Stevenson
Radiation Oncology
Expertise in
15
conditions
Dr. James Stevenson
Radiation Oncology

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (29.8 miles away)
216-636-6888
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Stevenson is a Radiation Oncologist practicing medicine in Cleveland, Ohio. Dr. Stevenson is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, and Small Cell Lung Cancer (SCLC).

Frequently Asked Questions about Dr. Desiree Doncals

How do I make an appointment with Dr. Desiree Doncals?

You can book an appointment with Dr. Desiree Doncals by calling their office at 330-375-3557. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Desiree Doncals a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Desiree Doncals is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Desiree Doncals specialize in?

While Dr. Desiree Doncals is a Radiation Oncology, they have specific expertise in Breast Cancer, Prostate Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Desiree Doncals participate in research or clinical trials?

Yes. Dr. Desiree Doncals has published 11 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Desiree Doncals's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Desiree Doncals accept my insurance?

Dr. Desiree Doncals accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 330-375-3557 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Doncals's expertise for a condition
ConditionClose
    View All 37 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile